Novel LRRK2 Kinase Inhibitors Enhance Phosphorylation and Restore Adapter Protein Binding in LRRK2 Variants
- 1Stanford University
Abstract
Autosomal dominant mutations in LRRK2 that increase kinase activity significantly increase the risk of developing Parkinson's disease (PD). Efforts to reduce the resulting hyperphosphorylation have focused mainly on small-molecule type I kinase inhibitors (KIs); however, these bind the active, closed conformation of the LRRK2 kinase domain, which affects protein tertiary structure and can alter other functions of this multi-domain protein. Because disruption of these functions may contribute to pathogenesis independently of, or in addition to, augmented kinase activity, inhibitors that engage LRRK2 differently may offer an advantage. We hypothesize that KIs, which bind distinct conformations of LRRK2 and modulate non-kinase functions differently than type I inhibitors, may be beneficial. Here we tested two series of LRRK2 inhibitors, based on hesperadin (series A) and GNF-7 (series B), which each inhibited LRRK2 kinase activity in biochemical and cellular assays while differing in effects on other LRRK2 functions. Interestingly, series B compounds enhanced phosphorylation of interdomain heterologous phosphosites and restored 14-3-3 binding in LRRK2 variants with suppressed phosphorylation. These chemotypes provide tools for dissecting the consequences of different inhibitor-bound LRRK2 conformations and support conformation-selective inhibition as a therapeutic strategy for PD.
Related
- Overcoming the Shield: Mechanisms of Resistance to DNA Repair Inhibitors and Strategies to Restore Synthetic Lethality
- Calcineurin inhibitors treatment in kidney transplant recipients is frequently associated with hyperkalemia, acidosis and hypertension but not with increased expression or phosphorylation of the sodium chloride cotransporter
- PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells
- Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV‑2 and Omicron Variants.
- AI-assisted image-based screening identifies TFEB agonists that restore adipose angiogenesis and reduce adipose fibrosis
BibTeX
@misc{garofalo2026novel,
title = {{Novel LRRK2 Kinase Inhibitors Enhance Phosphorylation and Restore Adapter Protein Binding in LRRK2 Variants}},
author = {A. W. Garofalo and M. D. Schonemann and M. Santoro and M. Adler and T. J. Montine},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.26.762006},
url = {https://www.biorxiv.org/content/10.64898/2026.10.26.762006v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Novel LRRK2 Kinase Inhibitors Enhance Phosphorylation and Restore Adapter Protein Binding in LRRK2 Variants
AU - A. W. Garofalo
AU - M. D. Schonemann
AU - M. Santoro
AU - M. Adler
AU - T. J. Montine
PY - 2026
DA - 2026/10/26
PB - bioRxiv
DO - 10.64898/2026.10.26.762006
UR - https://www.biorxiv.org/content/10.64898/2026.10.26.762006v1
AB - Autosomal dominant mutations in LRRK2 that increase kinase activity significantly increase the risk of developing Parkinson's disease (PD). Efforts to reduce the resulting hyperphosphorylation have focused mainly on small-molecule type I kinase inhibitors (KIs); however, these bind the active, closed conformation of the LRRK2 kinase domain, which affects protein tertiary structure and can alter other functions of this multi-domain protein. Because disruption of these functions may contribute to pathogenesis independently of, or in addition to, augmented kinase activity, inhibitors that engage LRRK2 differently may offer an advantage. We hypothesize that KIs, which bind distinct conformations of LRRK2 and modulate non-kinase functions differently than type I inhibitors, may be beneficial. Here we tested two series of LRRK2 inhibitors, based on hesperadin (series A) and GNF-7 (series B), which each inhibited LRRK2 kinase activity in biochemical and cellular assays while differing in effects on other LRRK2 functions. Interestingly, series B compounds enhanced phosphorylation of interdomain heterologous phosphosites and restored 14-3-3 binding in LRRK2 variants with suppressed phosphorylation. These chemotypes provide tools for dissecting the consequences of different inhibitor-bound LRRK2 conformations and support conformation-selective inhibition as a therapeutic strategy for PD.
ER -